Addex Therapeutics Ltd. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of December 2021 for Addex Therapeutics Ltd., a foreign private issuer. The report primarily addresses the termination of a specific Sales Agreement Prospectus related to an "at the market" (ATM) offering of common stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the ATM offering activity:
- Shares Issued: 1,200 ADSs (representing 7,200 ordinary shares) from June 29, 2021, through December 13, 2021.
- Average Price: $10.12 per ADS.
- Gross Proceeds: Approximately $12,000.
- Offering Capacity: The terminated prospectus allowed for aggregate sales up to $16.0 million.
Material Changes
The primary material change is the termination of the Sales Agreement Prospectus on December 15, 2021. While the underlying Sales Agreement with Cantor Fitzgerald & Co. remains in full force and effect, the Company will not make any further sales of ADSs under this agreement until a new prospectus is filed.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the prospectus termination. The filing incorporates by reference a press release (Exhibit 99.1) and material U.S. income tax considerations and supplemental risk factors (Exhibit 99.2). No specific forward-looking guidance or operational outlook is provided within the text of this filing.
Key Facts for Investor Verification
- Verify the status of the underlying Sales Agreement with Cantor Fitzgerald & Co. to confirm if a new prospectus has been filed to resume ATM offerings.
- Review the attached press release (Exhibit 99.1) for additional context on the termination decision.
- Consult the supplemental risk factors (Exhibit 99.2) for updated U.S. income tax considerations for holders.
- Note that gross proceeds from the terminated prospectus were minimal ($12,000) relative to the authorized $16.0 million capacity.